These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 19459807)

  • 21. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome.
    Sellier-Leclerc AL; Fremeaux-Bacchi V; Dragon-Durey MA; Macher MA; Niaudet P; Guest G; Boudailliez B; Bouissou F; Deschenes G; Gie S; Tsimaratos M; Fischbach M; Morin D; Nivet H; Alberti C; Loirat C;
    J Am Soc Nephrol; 2007 Aug; 18(8):2392-400. PubMed ID: 17599974
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome.
    Moore I; Strain L; Pappworth I; Kavanagh D; Barlow PN; Herbert AP; Schmidt CQ; Staniforth SJ; Holmes LV; Ward R; Morgan L; Goodship TH; Marchbank KJ
    Blood; 2010 Jan; 115(2):379-87. PubMed ID: 19861685
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The complement factor H R1210C mutation is associated with atypical hemolytic uremic syndrome.
    Martinez-Barricarte R; Pianetti G; Gautard R; Misselwitz J; Strain L; Fremeaux-Bacchi V; Skerka C; Zipfel PF; Goodship T; Noris M; Remuzzi G; de Cordoba SR;
    J Am Soc Nephrol; 2008 Mar; 19(3):639-46. PubMed ID: 18235085
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Membrane cofactor protein and factor I: mutations and transplantation.
    Kavanagh D; Goodship TH
    Semin Thromb Hemost; 2006 Mar; 32(2):155-9. PubMed ID: 16575690
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transplantation in atypical hemolytic uremic syndrome.
    Kavanagh D; Richards A; Goodship T; Jalanko H
    Semin Thromb Hemost; 2010 Sep; 36(6):653-9. PubMed ID: 20865642
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Insights into hemolytic uremic syndrome: segregation of three independent predisposition factors in a large, multiple affected pedigree.
    Esparza-Gordillo J; Jorge EG; Garrido CA; Carreras L; López-Trascasa M; Sánchez-Corral P; de Córdoba SR
    Mol Immunol; 2006 Apr; 43(11):1769-75. PubMed ID: 16386793
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis, and the HELLP syndrome.
    Fang CJ; Fremeaux-Bacchi V; Liszewski MK; Pianetti G; Noris M; Goodship TH; Atkinson JP
    Blood; 2008 Jan; 111(2):624-32. PubMed ID: 17914026
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Atypical hemolytic uremic syndrome.
    Loirat C; Frémeaux-Bacchi V
    Orphanet J Rare Dis; 2011 Sep; 6():60. PubMed ID: 21902819
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is the atypical hemolytic uremic syndrome risk polymorphism in Membrane Cofactor Protein MCPggaac relevant in kidney transplantation? A case report.
    Sánchez-Moreno A; de la Cerda F; Rodríguez-Barba A; Fijo J; Bedoya R; Arjona E; de Córdoba SR
    Pediatr Transplant; 2021 May; 25(3):e13903. PubMed ID: 33217135
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mutations in components of complement influence the outcome of Factor I-associated atypical hemolytic uremic syndrome.
    Bienaime F; Dragon-Durey MA; Regnier CH; Nilsson SC; Kwan WH; Blouin J; Jablonski M; Renault N; Rameix-Welti MA; Loirat C; Sautés-Fridman C; Villoutreix BO; Blom AM; Fremeaux-Bacchi V
    Kidney Int; 2010 Feb; 77(4):339-49. PubMed ID: 20016463
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Kidney Transplantation in Patients with Atypical Hemolytic Uremic Syndrome due to Complement Factor H Deficiency: Impact of Liver Transplantation.
    Kim S; Park E; Min SI; Yi NJ; Ha J; Ha IS; Cheong HI; Kang HG
    J Korean Med Sci; 2018 Jan; 33(1):e4. PubMed ID: 29215813
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Atypical hemolytic uremic syndrome: update on the complement system and what is new.
    Hirt-Minkowski P; Dickenmann M; Schifferli JA
    Nephron Clin Pract; 2010; 114(4):c219-35. PubMed ID: 20090363
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of eculizumab and plasma exchange in successful combined liver-kidney transplantation in a case of atypical HUS associated with complement factor H mutation.
    Tran H; Chaudhuri A; Concepcion W; Grimm PC
    Pediatr Nephrol; 2014 Mar; 29(3):477-80. PubMed ID: 24221349
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Common genetic variants in complement genes other than CFH, CD46 and the CFHRs are not associated with aHUS.
    Ermini L; Goodship TH; Strain L; Weale ME; Sacks SH; Cordell HJ; Fremeaux-Bacchi V; Sheerin NS
    Mol Immunol; 2012 Jan; 49(4):640-8. PubMed ID: 22153652
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome.
    Kavanagh D; Kemp EJ; Mayland E; Winney RJ; Duffield JS; Warwick G; Richards A; Ward R; Goodship JA; Goodship TH
    J Am Soc Nephrol; 2005 Jul; 16(7):2150-5. PubMed ID: 15917334
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome.
    Weitz M; Amon O; Bassler D; Koenigsrainer A; Nadalin S
    Pediatr Nephrol; 2011 Aug; 26(8):1325-9. PubMed ID: 21556717
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The interactive Factor H-atypical hemolytic uremic syndrome mutation database and website: update and integration of membrane cofactor protein and Factor I mutations with structural models.
    Saunders RE; Abarrategui-Garrido C; Frémeaux-Bacchi V; Goicoechea de Jorge E; Goodship TH; López Trascasa M; Noris M; Ponce Castro IM; Remuzzi G; Rodríguez de Córdoba S; Sánchez-Corral P; Skerka C; Zipfel PF; Perkins SJ
    Hum Mutat; 2007 Mar; 28(3):222-34. PubMed ID: 17089378
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A mutation in factor I that is associated with atypical hemolytic uremic syndrome does not affect the function of factor I in complement regulation.
    Nilsson SC; Karpman D; Vaziri-Sani F; Kristoffersson AC; Salomon R; Provot F; Fremeaux-Bacchi V; Trouw LA; Blom AM
    Mol Immunol; 2007 Mar; 44(8):1835-44. PubMed ID: 17084897
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recurrence of HUS due to CD46/MCP mutation after renal transplantation: a role for endothelial microchimerism.
    Frémeaux-Bacchi V; Arzouk N; Ferlicot S; Charpentier B; Snanoudj R; Dürrbach A
    Am J Transplant; 2007 Aug; 7(8):2047-51. PubMed ID: 17617869
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of mutations in complement factor I (CFI) associated with hemolytic uremic syndrome.
    Kavanagh D; Richards A; Noris M; Hauhart R; Liszewski MK; Karpman D; Goodship JA; Fremeaux-Bacchi V; Remuzzi G; Goodship TH; Atkinson JP
    Mol Immunol; 2008 Jan; 45(1):95-105. PubMed ID: 17597211
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.